Expression of PTEN and β-Catenin and Their Relationship With Clinicopathological and Prognostic Factors in Endometrioid Type Endometrial Cancer

Sal, Veysel; Demirkıran, Fuat; Erenel, Hakan; Tokgözoğlu, Nedim; Kahramanoğlu, İlker; Beşe, Tugan; Turan, Hasan; Sofiyeva, Nigar; Calay, Zerrin; Arvas, Macit; Güralp, Onur

doi:10.1097/igc.0000000000000626

Cited by 13 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The best known include the lossof-function mutations in suppressor gene PTEN, leading to the loss of its activity and consequent activation of cell proliferation stimulation along the whole pathway. These have been described mainly in endometrial carcinoma, glioblastoma, or prostatic cancer [21][22][23]. Other well-known include activating point mutations of PIK3CA and AKT gene amplification.…”

Section: Phosphatidyl-inositol 3-kinase Signalling Pathwaymentioning

confidence: 99%

“…Conversely, loss of PTEN gene expression results in increased AKT activity and continued cell proliferation. Deletions and missense point mutations leading to PTEN gene inactivation are the most frequently observed genetic aberrations found in a variety of neoplasms such as prostatic, breast, lung, endometrial, and colorectal cancers or glioblastomas [21,23,26,[64][65][66][67][68]. Total suppression of the PTEN gene expression is lethal to embryonic cells, and partial suppression leads to carcinogenesis [40].…”

Section: Phosphatase and Tensin Homologue Deleted On Chromosome 10mentioning

confidence: 99%

“…Total suppression of the PTEN gene expression is lethal to embryonic cells, and partial suppression leads to carcinogenesis [40]. The prognostic significance of PTEN gene inactivation has been described mainly in uterus, breast, prostate, and lung cancer or malignant melanoma [21,23,65,66,69].…”

Section: Phosphatase and Tensin Homologue Deleted On Chromosome 10mentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review

et al. 2021

View full text Add to dashboard Cite

Over 260,000 (2013) new oral squamous cell carcinoma (OSCC) cases are reported annually worldwide. Despite development in OSCC management, the outcome is still unsatisfactory. Identification of new molecular markers may be of use in prevention, prognosis, and choice of an appropriate therapy.The intracellular molecular signalling pathway of phosphatidyl-inositol-3-kinase is involved in the process of cell growth, differentiation, migration, and survival. The main components of this pathway: PIK3CA (phosphatidylinositol-4,5-bisphosphate-3-kinase catalytic subunit ), PTEN (phosphatase and tensin homologue deleted on chromosome 10), and AKT (serine-threonine kinase) are potential objects of research when introducing new therapeutic agents. The aim of this paper is to evaluate the PIK3CA, PTEN, and AKT gene mutations as prognostic factors in OSCC and to describe their role in aggressive disease progression. This is crucial for oral cancer biology understanding and for indicating which direction new clinical treatments should take.

show abstract

Section: Phosphatidyl-inositol 3-kinase Signalling Pathwaymentioning

confidence: 99%

Section: Phosphatase and Tensin Homologue Deleted On Chromosome 10mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…CCL2 (targeted by enhancer chr17:32559802–32586800) is important for regulating cell growth and survival by inhibiting necrosis and autophagy and is overexpressed in luminal B breast cancer cells and [ 49 ]. For endometrial cancer, it was indicated that high expression of PTEN targeted by enhancer chr17:5519002–5520600 is positively correlated with myometrial invasion in endometrial cancer [ 50 ]. Expression of BCL2 (targeted by two enhancers chr15:54202002–54203000 and chr15:54203002–54203600) is significantly more frequent in early clinical stages in both types of endometrial cancer [ 51 ].…”

Section: Resultsmentioning

confidence: 99%

A network-based method for predicting disease-associated enhancers

2021

PLoS ONE

View full text Add to dashboard Cite

Background Enhancers regulate transcription of target genes, causing a change in expression level. Thus, the aberrant activity of enhancers can lead to diseases. To date, a large number of enhancers have been identified, yet a small portion of them have been found to be associated with diseases. This raises a pressing need to develop computational methods to predict associations between diseases and enhancers. Results In this study, we assumed that enhancers sharing target genes could be associated with similar diseases to predict the association. Thus, we built an enhancer functional interaction network by connecting enhancers significantly sharing target genes, then developed a network diffusion method RWDisEnh, based on a random walk with restart algorithm, on networks of diseases and enhancers to globally measure the degree of the association between diseases and enhancers. RWDisEnh performed best when the disease similarities are integrated with the enhancer functional interaction network by known disease-enhancer associations in the form of a heterogeneous network of diseases and enhancers. It was also superior to another network diffusion method, i.e., PageRank with Priors, and a neighborhood-based one, i.e., MaxLink, which simply chooses the closest neighbors of known disease-associated enhancers. Finally, we showed that RWDisEnh could predict novel enhancers, which are either directly or indirectly associated with diseases. Conclusions Taken together, RWDisEnh could be a potential method for predicting disease-enhancer associations.

show abstract

“…PTEN sub-expression rates, as well as key genes in the PI3K and β-catenin pathways, are positively related to myometrial invasion in endometrioid carcinoma. PTEN is also associated with increased myometrial invasion, but nonetheless, PTEN and β-catenin overexpression show no significant association with 5-year OS or RFS; thus, the association of PTEN and β-catenin with long-term survival remains to be determined [ 69 ]. Obesity is a risk factor related to EC due to PI3K pathway and insulin signaling mutations, which occur in most endometrioid adenocarcinomas.…”

Section: Resultsmentioning

confidence: 99%

Prognostic molecular biomarkers in endometrial cancer: A review

Hernandez¹,

González-Montiel²,

Allos-Villalva³

et al. 2019

J Cancer Res Ther.

View full text Add to dashboard Cite

Background: Endometrial cancer (EC) is the fourth most common malignancy in women worldwide and the most common gynecological cancer in developed countries. The endometrioid subtype has an excellent prognosis with conventional treatment; however, recurrence reduces overall survival. Objective: Describe the most relevant evidence regarding selected potential molecular biomarkers that may predict overall survival (OS), relapse-free survival (RFS), and cancer-specific survival (CSS) in EC. Methods: An exhaustive search was performed in PUBMED with the search terms endometrial cancer, molecular biomarker, and survival. We selected original articles written in English about endometrial cancer, molecular biomarkers, and that included survival analysis published between January 2000 and December 2016. Results: Several molecular prognostic biomarkers have been studied in terms of survival and therapeutic response in women with endometrial cancer; hormone receptors, microRNAs, and other molecules have emerged as potentially useful biomarkers, including HER2, p21, HE4, PTEN, p27, ANCCA, and ANXA2. Conclusions: The use of biomarkers in the assessment of OS, RFS, and CSS requires large trials to expand our understanding of endometrial carcinogenesis. Several molecular markers are significantly associated with a high tumor grade and advanced clinical stage in EC and, therefore, could have additive effects when combined.

show abstract

Expression of PTEN and β-Catenin and Their Relationship With Clinicopathological and Prognostic Factors in Endometrioid Type Endometrial Cancer

Cited by 13 publications

References 33 publications

Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review

Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review

A network-based method for predicting disease-associated enhancers

Prognostic molecular biomarkers in endometrial cancer: A review

Contact Info

Product

Resources

About